墨西哥成人艾滋病毒感染者丙型肝炎病毒合并感染的流行率：一项全国代表性样本的横断面血清流行率研究

IF 7 Q1 HEALTH CARE SCIENCES & SERVICES

Lancet Regional Health-Americas Pub Date : 2025-01-01 DOI:10.1016/j.lana.2024.100965

Pablo F. Belaunzarán-Zamudio , Juan L. Mosqueda-Gómez , J. Oggún Cano-Torres , Claudia Guillén-López , Teresa Muñoz-Trejo , Kenia Escobedo-López , Alejandro Rivera-Marroquín , Akio Murakami-Ogasawara , José L. Sánchez-Bello , Margarita M. Rosas-Dossetti , Elizabeth Papaqui-Limón , Alethse De la Torre-Rosas , Juana Díaz-García , Juan G. Sierra-Madero

{"title":"墨西哥成人艾滋病毒感染者丙型肝炎病毒合并感染的流行率：一项全国代表性样本的横断面血清流行率研究","authors":"Pablo F. Belaunzarán-Zamudio , Juan L. Mosqueda-Gómez , J. Oggún Cano-Torres , Claudia Guillén-López , Teresa Muñoz-Trejo , Kenia Escobedo-López , Alejandro Rivera-Marroquín , Akio Murakami-Ogasawara , José L. Sánchez-Bello , Margarita M. Rosas-Dossetti , Elizabeth Papaqui-Limón , Alethse De la Torre-Rosas , Juana Díaz-García , Juan G. Sierra-Madero","doi":"10.1016/j.lana.2024.100965","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.</div></div><div><h3>Methods</h3><div>Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico. We tested serum for anti-HCV IgG antibodies and collected data on risky exposures. We estimated the seroprevalence of HCV and associated exposures using regression models and the Taylor linearization method to account for the cluster effect by region and centre.</div></div><div><h3>Findings</h3><div>We collected blood samples of 2545 participants. Most participants were men (75.8%) with a median age of 37 years. The estimated seroprevalence of HCV is 3.9% (95% CI 3.1%–4.7%). Only 39 of 99 participants (40%) with HCV antibodies had active replication determined by RNA quantification. Seroprevalence of HCV was significantly higher among people with life-time history of imprisonment (9%, 95% CI 4.4%–13.6%), tattoo use (5.9%, 95% CI 3.9%–8%), and lifetime (22.3%, 95% CI 12.1%–32.6%) and recent (49.3%, 95% CI 18.3%–80.3%) injecting-drug use.</div></div><div><h3>Interpretation</h3><div>Seroprevalence of HCV infection among PLWHIV in Mexico is ten times as high as the seroprevalence for the general population. The national program for HCV elimination focused in PLWHIV should target people that use injecting drugs and living in prisons.</div></div><div><h3>Funding</h3><div><span>Abbvie Farmacéuticos</span>, S.A de C.V Mexico through Investigator Initiated Study (2018).</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"41 ","pages":"Article 100965"},"PeriodicalIF":7.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732492/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of hepatitis C virus co-infection in adults living with HIV in Mexico: a cross-sectional, seroprevalence study in a nationally representative sample\",\"authors\":\"Pablo F. Belaunzarán-Zamudio , Juan L. Mosqueda-Gómez , J. Oggún Cano-Torres , Claudia Guillén-López , Teresa Muñoz-Trejo , Kenia Escobedo-López , Alejandro Rivera-Marroquín , Akio Murakami-Ogasawara , José L. Sánchez-Bello , Margarita M. Rosas-Dossetti , Elizabeth Papaqui-Limón , Alethse De la Torre-Rosas , Juana Díaz-García , Juan G. Sierra-Madero\",\"doi\":\"10.1016/j.lana.2024.100965\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.</div></div><div><h3>Methods</h3><div>Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico. We tested serum for anti-HCV IgG antibodies and collected data on risky exposures. We estimated the seroprevalence of HCV and associated exposures using regression models and the Taylor linearization method to account for the cluster effect by region and centre.</div></div><div><h3>Findings</h3><div>We collected blood samples of 2545 participants. Most participants were men (75.8%) with a median age of 37 years. The estimated seroprevalence of HCV is 3.9% (95% CI 3.1%–4.7%). Only 39 of 99 participants (40%) with HCV antibodies had active replication determined by RNA quantification. Seroprevalence of HCV was significantly higher among people with life-time history of imprisonment (9%, 95% CI 4.4%–13.6%), tattoo use (5.9%, 95% CI 3.9%–8%), and lifetime (22.3%, 95% CI 12.1%–32.6%) and recent (49.3%, 95% CI 18.3%–80.3%) injecting-drug use.</div></div><div><h3>Interpretation</h3><div>Seroprevalence of HCV infection among PLWHIV in Mexico is ten times as high as the seroprevalence for the general population. The national program for HCV elimination focused in PLWHIV should target people that use injecting drugs and living in prisons.</div></div><div><h3>Funding</h3><div><span>Abbvie Farmacéuticos</span>, S.A de C.V Mexico through Investigator Initiated Study (2018).</div></div>\",\"PeriodicalId\":29783,\"journal\":{\"name\":\"Lancet Regional Health-Americas\",\"volume\":\"41 \",\"pages\":\"Article 100965\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732492/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Regional Health-Americas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667193X24002928\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Americas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667193X24002928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

背景：墨西哥艾滋病毒感染者（PLWHIV）合并丙型肝炎病毒感染者的比例尚不清楚。我们的目的是估计墨西哥成年HIV感染者中HCV的血清患病率。方法：采用复杂调查设计，于2019年5月2日至2020年2月17日在墨西哥8个社会人口统计学区域的24个随机选择的艾滋病毒护理中心收集血液样本并应用结构化问卷，在全国范围内具有代表性的成年人接受艾滋病毒感染护理。我们检测了血清抗丙型肝炎病毒IgG抗体，并收集了危险暴露的数据。我们使用回归模型和Taylor线性化方法来估计HCV的血清患病率和相关暴露，以解释区域和中心的聚类效应。研究结果：我们收集了2545名参与者的血液样本。大多数参与者为男性（75.8%），中位年龄为37岁。估计HCV的血清患病率为3.9% （95% CI 3.1%-4.7%）。99名携带HCV抗体的参与者中只有39名（40%）通过RNA定量检测有活跃复制。有终身监禁史（9%,95% CI 4.4%-13.6%）、纹身史（5.9%,95% CI 3.9%-8%）、终身注射吸毒者（22.3%,95% CI 12.1%-32.6%）和近期注射吸毒者（49.3%,95% CI 18.3%-80.3%）的HCV血清阳性率明显较高。解释：在墨西哥，艾滋病毒感染者中HCV感染的血清阳性率是普通人群血清阳性率的十倍。以艾滋病毒感染者为重点的国家消除丙型肝炎病毒规划应针对注射毒品使用者和监狱生活人员。资助：艾伯维农场，S.A de c.v.墨西哥通过研究者发起的研究（2018）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prevalence of hepatitis C virus co-infection in adults living with HIV in Mexico: a cross-sectional, seroprevalence study in a nationally representative sample

Background

The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.

Methods

Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico. We tested serum for anti-HCV IgG antibodies and collected data on risky exposures. We estimated the seroprevalence of HCV and associated exposures using regression models and the Taylor linearization method to account for the cluster effect by region and centre.

Findings

We collected blood samples of 2545 participants. Most participants were men (75.8%) with a median age of 37 years. The estimated seroprevalence of HCV is 3.9% (95% CI 3.1%–4.7%). Only 39 of 99 participants (40%) with HCV antibodies had active replication determined by RNA quantification. Seroprevalence of HCV was significantly higher among people with life-time history of imprisonment (9%, 95% CI 4.4%–13.6%), tattoo use (5.9%, 95% CI 3.9%–8%), and lifetime (22.3%, 95% CI 12.1%–32.6%) and recent (49.3%, 95% CI 18.3%–80.3%) injecting-drug use.

Interpretation

Seroprevalence of HCV infection among PLWHIV in Mexico is ten times as high as the seroprevalence for the general population. The national program for HCV elimination focused in PLWHIV should target people that use injecting drugs and living in prisons.

Funding

Abbvie Farmacéuticos, S.A de C.V Mexico through Investigator Initiated Study (2018).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Regional Health-Americas Multiple-

CiteScore

8.00

自引率

0.00%

发文量

期刊介绍： The Lancet Regional Health – Americas, an open-access journal, contributes to The Lancet's global initiative by focusing on health-care quality and access in the Americas. It aims to advance clinical practice and health policy in the region, promoting better health outcomes. The journal publishes high-quality original research advocating change or shedding light on clinical practice and health policy. It welcomes submissions on various regional health topics, including infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, emergency care, health policy, and health equity.